In recent years, China has helped to solve the problem of drug accessibility for rare diseases through the adjustment of the medical insurance catalogue. For example, in the adjustment of the national health insurance catalogue in 2019, the drugs for rare diseases such as rare diseases were mainly considered, the drugs for primary carnitine deficiency and young Parkinsons disease were added into the list, and the drugs for pulmonary hypertension and type C Niemann Picks disease were included in the entry negotiation Record. According to statistics, among the 121 kinds of rare disease treatment drugs in the world, there are more than 50 kinds of rare disease treatment drugs listed in China and have indications. Among them, more than 40 kinds have been included in the national medical insurance drug list, and the price has dropped sharply.
However, up to now, there is no unified standard on how to enter the medical insurance system through access negotiation for rare disease drugs, especially some high price drugs.
Song Ruilin, executive chairman of China pharmaceutical innovation promotion association, told reporters from China first finance and economics that rare diseases are characterized by a low number of patients, so it is difficult for pharmaceutical companies to obtain reasonable profit returns after developing drugs for rare diseases. The high price of rare disease drugs is related to the high cost of R & D and production. To solve the problem of high price of rare disease drugs, we cant just reduce the price, because if the price drops too much, the enterprise will not have the motivation to further research and development. To solve the problem of drug accessibility for rare diseases, on the one hand, enterprises should be able to reduce costs and pursue reasonable profits. On the other hand, a reasonable reimbursement system should be established Song Ruilin said so.
At the Fifth China Pharmaceutical Innovation and investment conference, Zhao Kun, deputy director of the center for drug and health technology evaluation of the National Health Commission, told reporters at the first finance and economics department and other people on the scene that the payment method of high-value new drugs for rare diseases can be explored based on individual efficacy. The medical insurance bureau and the drug administration will establish individual level efficacy indicators based on clinical trial data, and the medical insurance bureau will also work with the health care Commission All rare patients receiving treatment must register with the national registration system for rare diseases before they can be reimbursed. Zhao Kun said: for example, the drug administration allows the drug development to be approved for listing after the second phase. The medical insurance bureau can first negotiate a price with the enterprise, and then the medical insurance bureau will evaluate the price according to the efficacy of the drug after it is put on the market. In this way, pharmaceutical enterprises and enterprises are expected to achieve a win-win situation.
However, many analysts believe that to solve the problem of drug access for rare diseases, we still need to find multiple payment methods. We cant push the payment of drugs for rare diseases to medical insurance, which cant afford such high prices. Instead, we need to explore a variety of payment methods, such as charity and commercial insurance, and use the strength of the whole society to solve the problem of drug access for rare diseases. Song Ruilin said. In addition, Li Linkang, executive director of the China rare diseases alliance, said that to solve the security of rare disease drugs, first, the country should establish a unified special guarantee plan for special and rare disease drugs; second, multi-channel fund-raising should be formed to form a unified fund plate; third, the government and society should work together to determine a reasonable management mode; fourth, to carry out centralized procurement negotiations to reduce drug prices; fifth, to formulate relevant policies Related supporting policies. Another giant of extended reading cant hold on? Nearly 70 years old stores in Japan are about to close down. The European Central Bank has released its first digital Euro report. The digital currency project will be launched as soon as next year. The trump government will take action against Google: an antitrust lawsuit can be filed as soon as next week. Source: editor in charge of Finance and Economics: Zhong Qiming_ NF5619
However, many analysts believe that to solve the problem of drug access for rare diseases, we still need to find multiple payment methods.
We cant push the payment of drugs for rare diseases to medical insurance, which cant afford such high prices. Instead, we need to explore a variety of payment methods, such as charity and commercial insurance, and use the strength of the whole society to solve the problem of drug access for rare diseases. Song Ruilin said.